Brii Biosciences Statistics
Total Valuation
Brii Biosciences has a market cap or net worth of 96.03 million. The enterprise value is -240.75 million.
| Market Cap | 96.03M |
| Enterprise Value | -240.75M |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.40% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 533.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 0.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 6.59 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 3.75 |
Financial Position
The company has a current ratio of 37.81, with a Debt / Equity ratio of 0.00.
| Current Ratio | 37.81 |
| Quick Ratio | 35.26 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -401.64 |
Financial Efficiency
Return on equity (ROE) is -9.18% and return on invested capital (ROIC) is -10.45%.
| Return on Equity (ROE) | -9.18% |
| Return on Assets (ROA) | -10.12% |
| Return on Capital (ROIC) | -10.45% |
| Revenue Per Employee | 55,595 |
| Profits Per Employee | -384,508 |
| Employee Count | 128 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.80% in the last 52 weeks. The beta is 1.45, so Brii Biosciences's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -71.80% |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 23.16 |
| Average Volume (20 Days) | 36,756 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Brii Biosciences had revenue of 5.28 million and -36.53 million in losses. Loss per share was -0.05.
| Revenue | 5.28M |
| Gross Profit | 5.28M |
| Operating Income | -67.93M |
| Pretax Income | -37.26M |
| Net Income | -36.53M |
| EBITDA | -67.22M |
| EBIT | -67.93M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 328.44 million in cash and 261,322 in debt, giving a net cash position of 328.18 million.
| Cash & Cash Equivalents | 328.44M |
| Total Debt | 261,322 |
| Net Cash | 328.18M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 386.73M |
| Book Value Per Share | 0.54 |
| Working Capital | 342.88M |
Cash Flow
In the last 12 months, operating cash flow was -64.13 million and capital expenditures -105,272, giving a free cash flow of -64.24 million.
| Operating Cash Flow | -64.13M |
| Capital Expenditures | -105,272 |
| Free Cash Flow | -64.24M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,286.14% |
| Pretax Margin | -705.53% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Brii Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.40% |
| Shareholder Yield | -0.40% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Brii Biosciences has an Altman Z-Score of 6.96.
| Altman Z-Score | 6.96 |
| Piotroski F-Score | n/a |